<--- Back to Details
First PageDocument Content
Medicine / Peptide hormones / Recombinant proteins / Diabetes / Anti-diabetic drugs / Insulin therapy / Exenatide / Intensive insulinotherapy / Anti-diabetic medication / Eli Lilly and Company / Endocrine system / Biology
Date: 2015-04-22 23:39:46
Medicine
Peptide hormones
Recombinant proteins
Diabetes
Anti-diabetic drugs
Insulin therapy
Exenatide
Intensive insulinotherapy
Anti-diabetic medication
Eli Lilly and Company
Endocrine system
Biology

Add to Reading List

Source URL: www.pbs.gov.au

Download Document from Source Website

File Size: 134,59 KB

Share Document on Facebook

Similar Documents

Dipeptidyl peptidase-4 inhibitors / Eli Lilly and Company / Amides / Anti-diabetic drugs / Peptide hormones / Exenatide / Anti-diabetic medication / Sitagliptin / Saxagliptin / Metformin / Glucagon-like peptide-1 agonist / Sulfonylurea

Official Newsletter of the Utah Poison Control Center 2010 • VOLUME 12 • ISSUE 4 T O D A Y NEW DRUGS FOR TREATMENT OF DIABETES

DocID: 1oY1K - View Document

Sulfonylureas / Eli Lilly and Company / Glimepiride / Pyrrolines / Pioglitazone / Metformin / Exenatide / Glibenclamide / Acarbose

glimepiride contraindications glimepiride doses glimepiride dehydration side effects of glimepiride glimepiride forum glimepiride tabs dosage, glimepiride max dose 10mg, glimepiride 2mg

DocID: 1oLgD - View Document

Medicine / Eli Lilly and Company / Gastroenterology / Anti-diabetic drugs / Recombinant proteins / Exenatide / Anti-diabetic medication / Insulin analog / Insulin glargine / Endocrine system / Diabetes / Peptide hormones

OctoberINSULIN USE FOR TYPE 2 DIABETES MANAGEMENT WHAT INSULIN REGIMEN SHOULD

DocID: 1fAJ9 - View Document

BYDUREON (exenatide extended-release for injectable suspension).

DocID: 1dnVP - View Document

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BYETTA safely and effectively. See full prescribing information for BYETTA. BYETTA姞 (exenatide) Injection Initial

DocID: 1ccpM - View Document